CCHR says the VA and DoD waste billions of dollars on treatments that contribute to high suicide rates, sudden deaths and ...

Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...

The global consumption of psychiatric medication is increasing by 4% annually, with the greatest increase observed in ...

Study hopes to inform the research agenda and help future research to focus on the questions that are most important to key stakeholders.

Factors to consider include the benefits of nursing, the wishes of the parents, the risk of infant exposure to medication, the severity of maternal psychiatric symptoms (and thus, the desirablity ...

In contrast to our findings, a diagnosis of drug dependence or nondependent ... much insight into factors affecting fall risk among psychiatric inpatients, its retrospective design is an inherent ...

This research uncovers the complex relationship between blood pressure treatment and mental health, advocating for ...

These are a class of drugs typically given to people who have serious depression and psychiatric issues. Their previous data ...

This journal utilises an Online Peer Review Service (OPRS) for submissions. By clicking "Continue" you will be taken to our partner site https://mc.manuscriptcentral ...

Hair loss is a common problem in clinical dermatology, with many aetiologies including but not limited to androgenetic ...

Emrosi is expected to be available in the first quarter or early second quarter of 2025. The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release ...